These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34996624)

  • 1. Panniculitis in patients treated with BRAF/MEK inhibitors: Presentation of 4 new cases.
    Cordeiro González P; Taibo Martínez A; Peña Penabad C
    Med Clin (Barc); 2022 Jun; 158(11):e8-e9. PubMed ID: 34996624
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabrafenib-induced neutrophilic panniculitis in a child undergoing dual BRAF-MEK inhibitor therapy for glioblastoma multiforme.
    Young TK; Gutierrez D; Criscito MC; Kim RH; Lakdawala N; Oza VS
    Pediatr Dermatol; 2020 Nov; 37(6):1185-1186. PubMed ID: 32869334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma.
    Carrabba NV; Siliezar PD; Laylani N; Lee AG
    Can J Ophthalmol; 2023 Dec; 58(6):e251-e253. PubMed ID: 37545048
    [No Abstract]   [Full Text] [Related]  

  • 4. [Subretinal fluid associated with MEK and BRAF inhibitors].
    Attia R; Comet A; Stolowy N; Fitoussi R; Michel T; Denis D; David T
    J Fr Ophtalmol; 2022 Nov; 45(9):1091-1092. PubMed ID: 35908992
    [No Abstract]   [Full Text] [Related]  

  • 5. BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval.
    Mullard A
    Nat Rev Drug Discov; 2022 Aug; 21(8):548. PubMed ID: 35794466
    [No Abstract]   [Full Text] [Related]  

  • 6. [Panniculitis during BRAF inhibitor and/or MEK inhibitor therapy: A new case report and literature review].
    Piroth M; Frénard C; Eugène-Lamer J; Dreno B; Quéreux G
    Ann Dermatol Venereol; 2020 Dec; 147(12):833-841. PubMed ID: 32948319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma.
    Demarez B; Eté M; David L; Quiles N; Archier E
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e688-e689. PubMed ID: 35398936
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulomatous Dermatitis in a Patient With Cholangiocarcinoma Treated With BRAF and MEK Inhibitors.
    Bormann JL; Kerkvliet AM
    Cutis; 2023 Sep; 112(3):E17-E20. PubMed ID: 37903392
    [No Abstract]   [Full Text] [Related]  

  • 10. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
    Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
    J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
    Buchacher L; Richtig G; Dernoscheg M; Richtig E; Koch L
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e605-e607. PubMed ID: 36645848
    [No Abstract]   [Full Text] [Related]  

  • 12. Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.
    Consoli F; Manganoni AM; Grisanti S; Petrelli F; Venturini M; Rangoni G; Guarneri F; Incardona P; Vermi W; Calzavara Pinton PG; Berruti A
    PLoS One; 2019; 14(4):e0214884. PubMed ID: 30939167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.
    Courand PY; Berger M; Bouali A; Harbaoui B; Lantelme P; Dalle S
    Curr Oncol Rep; 2022 Mar; 24(3):265-271. PubMed ID: 35102484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens.
    Le Goubey JB; Sassier M; Nakouri I; De Pontville M; Césaire L; Aide N; Kottler D
    Melanoma Res; 2023 Apr; 33(2):159-161. PubMed ID: 36815470
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment.
    Obaru C; Kimura T; Yamamura M; Kuriyama H; Kashiwada-Nakamura K; Mizuhashi S; Matsumura T; Watanabe T; Inoue T; Fukushima S
    J Dermatol; 2024 Apr; 51(4):e115-e117. PubMed ID: 37927219
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment combinations in BRAF-mutant metastatic melanoma.].
    Depenni R
    Recenti Prog Med; 2021 Apr; 112(4):40e-43e. PubMed ID: 33877098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panniculitis Under Successful Targeted Inhibition of the MAPK/ERK Signaling Pathway in a Patient With BRAF V600E-mutated Spindle Cell Oncocytoma of the Pituitary Gland.
    Sollfrank L; Lettmaier S; Erdmann M; Uslu U
    Anticancer Res; 2019 Jul; 39(7):3955-3959. PubMed ID: 31262927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.
    Butt SU; Mejias A; Morelli C; Torga G; Happe M; Patrikidou A; Arkenau HT
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):437-441. PubMed ID: 33537843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting.
    Pedersen S; Larsen KO; Christensen AH; Svane IM; Zerahn B; Ellebaek E
    Acta Oncol; 2022 Jan; 61(1):45-51. PubMed ID: 34666597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.
    Mukai K; Kamata M; Miyazaki M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Ishikawa T; Ohnishi T; Tada Y; Tanaka T
    J Dermatol; 2021 May; 48(5):707-709. PubMed ID: 33600004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.